Aerie Pharma (AERI): Raising PT On Roclatan Data - Needham
Tweet Send to a Friend
Needham & Company analyst, Serge Belanger, reiterated his Buy rating on shares of Aerie Pharma (NASDAQ: AERI) and raised his ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


